HotPennyStockNews.com is devoted to fetch you the most exclusive stocks in the market today. Apart from scanning the markets for the most underrated stocks. We propel those victors directly to your email inbox first ahead of the rest of the marketplace gets a prospect.
Los Angelas, CA -- (SBWIRE) -- 11/08/2012 -- Pfizer (NYSE:PFE) and the specialty biopharmaceutical firm Auxilium Pharmaceuticals (NASDAQ:AUXL) have modified their collaboration agreement for the development, commercialization and production of Xiapex in the European Union and in certain other European and Eurasian countries. Through its terms, the Collaboration Agreement will conclude no later than April 24, 2013, but before the mutual termination date, the parties will continue to perform all of their obligations as required in the Collaboration Agreement. Subsequent to the termination date, all rights to commercialize Xiapex and responsibility for regulatory activities for Xiapex in these countries will revert to Auxilium, which at that point will recognize $94 million of deferred revenue along with $9 million of deferred costs in the fourth quarter. Pfizer, Inc. Comm (NYSE:PFE) is -0.32 - -1.31% from the previous close of $24.49. It traded between $23.99 - 24.62 with total traded volume of 49394808 shares. At Current Market Price, PFE is in distance of -3.60% from its 50-day Moving Average price of $25.0738 and +2.58% from its 200-day Moving Average price of $23.561.
Can PFE Continue To Move Higher? CHECK HERE To Know More
James River Coal Company (NASDAQ:JRCC) Third-quarter results showed a net loss of $0.59 per diluted share, bringing losses for the first nine months of the year to $1.78 per diluted share. Production for the quarter dropped by about 600 tons, while revenue per ton dropped from $92.18 to $83.64. However, the cost of coal sold dropped by about 30 cents per ton. “Despite the soft coal markets, we continue to be pleased with the performance of our mine operations team,” commented chairman and CEO Peter Socha in the release. “They made a series of adjustments to their operating plans in response to the current markets. In the financial area, we decided to take the opportunity to reduce our debt at very advantageous market prices due to external events.” The company was able to repurchase $61.4 million in debt at about 39 cents on the dollar. James River Coal (NasdaqNM:JRCC) is -1.41 - -30.00% from the previous close of $4.70. It traded between $3.20 - 4.00 with total traded volume of 10396012 shares. At Current Market Price, JRCC is in distance of -14.57% from its 50-day Moving Average price of $3.8512 and +4.83% from its 200-day Moving Average price of $3.1383.
Can JRCC Bounce Back And Start Rally From Here? To Know More CHECK HERE
Shares of contract electronics manufacturer Plexus (Nasdaq:PLXS) crashed 28% today after announcing that it will no longer be a supplier to networking gear maker Juniper Networks (NYSE: JNPR) . Juniper happens to be Plexus' largest customer, accounting for 17% of its business in fiscal year 2011, so investors have no choice but to model considerably lower revenue going forward. Although Plexus didn't give a reason for Juniper's decision, some analysts suspect that pricing was the issue, sparking concerns that it might need to give its other customers some margin-crimping concessions to prevent further contract losses. Plexus Corp. (NasdaqNM:PLXS) is -7.45 - -26.65% from the previous close of $27.96. It traded between $19.63 - 21.08 with total traded volume of 2568016 shares. Keep a close eye on PLXS, as the stock has been showing unusual moves over the past weeks. At Current market price, PLXS has recovered -11.71% from its 52-week Low of 23.23 and has Pulled back -46.73% from its 52-week high of 38.50.
Collect The Full Research Report On PLXS For Free: CLICK HERE
STEC Inc. (NASDAQ:STEC) reported third quarter 2012 adjusted loss per share of 33 cents, narrower than the Zacks Consensus Estimate of 36 cents loss per share. The adjusted or non-GAAP loss per share excludes employee severance fees, litigation costs and deferred tax valuation allowance, but includes stock-based compensation expense. The quarter’s earnings dropped 451.0% from the year-ago level. The disappointing result was due to higher costs, lower pricing and market share loss. Total revenue for the third quarter was $42.1 million, down 42.0% on a year-over-year basis. The sales decline was due to market share loss. Total revenue for the third quarter was $42.1 million, down 42.0% on a year-over-year basis. The sales decline was due to market share loss. Reported gross margin in the quarter was 37.0%, down from 45.8% in the year-ago quarter. Higher percentage of fixed production overhead and labor costs on revenue and competitive pricing pulled down the gross margin. This was partially offset by favorable flash-component costs.
Should Investor Hold or wait For Correction: Find Out Now
Disclaimer
Neither HotPennyStockNews.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor or broker dealer in any jurisdiction whatsoever and none of the information provided by HotPennyStockNews.com, owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or an investment recommendation. HotPennyStockNews.com makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through HotPennyStockNews.com. Investing in securities is speculative and carries a high degree of risk and no investment should be made unless you can afford to loose your entire investment. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. Please consult a broker before purchasing or selling any securities viewed on or mentioned here
in..
Contact:
hotpennystocknews.com
info@hotpennystocknews.com
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-321-1250 (International)